Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What are Viruses?00:50

What are Viruses?

128.0K
Overview
128.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

269
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
269
Hepatic Portal System01:21

Hepatic Portal System

5.7K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

224
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
224
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

562
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
562
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

306
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
306

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotypic and phenotypic characteristics of CXCR4-using transmitted/founder HIV-1 envelope glycoproteins.

Journal of virology·2026
Same author

Evidence of Rat Hepatitis E Virus Circulation through Wastewater Surveillance, Central Argentina.

Emerging infectious diseases·2026
Same author

Delta Describe, the French Collaborative Project: The Profile and Management of Hepatitis Delta Patients in Metropolitan France.

Viruses·2026
Same author

Evaluation of a New Automated Platform for the Detection and Quantification of HEV RNA.

Journal of medical virology·2026
Same author

Two decades of hepatitis E in solid organ transplantation: A retrospective monocentric analysis.

Hepatology (Baltimore, Md.)·2026
Same author

A Computational Structural Analysis of Host Insertions in the Polyproline Region of the Hepatitis E Virus pORF1 Polyprotein.

Viruses·2026
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Related Experiment Video

Updated: Jan 27, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

[Hepatitis E virus infection].

Olivier Marion1, Jacques Izopet2, Nassim Kamar3

  • 1Département de néphrologie et transplantation d'organes, hôpital Rangueil. Inserm UMR1043, centre de physiopathologie de Toulouse-Purpan.

La Revue Du Praticien
|March 15, 2019
PubMed
Summary
This summary is machine-generated.

Hepatitis E virus (HEV) infection is an emerging zoonotic disease in Western Europe, primarily affecting immunocompromised individuals and potentially leading to chronic liver disease. Treatment with ribavirin may be necessary for viral clearance in persistent cases.

Keywords:
Hepatitis E virus infection

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K

Related Experiment Videos

Last Updated: Jan 27, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • Hepatitis E virus (HEV) is endemic in developed countries, particularly Western Europe.
  • Transmission occurs via undercooked meat from pigs or game, classifying HEV as a zoonotic agent.
  • HEV infection is typically self-limiting in immunocompetent individuals.

Purpose of the Study:

  • To review the epidemiology and clinical significance of Hepatitis E virus infection.
  • To highlight the risks and management of HEV in immunocompromised patient populations.
  • To discuss emerging extra-hepatic manifestations of HEV infection.

Main Methods:

  • Literature review of HEV epidemiology and clinical outcomes.
  • Analysis of HEV transmission routes and risk factors.
  • Summary of treatment strategies for chronic HEV infection.

Main Results:

  • HEV poses a significant risk for chronic hepatitis and cirrhosis in immunocompromised patients, including transplant recipients and those with HIV or undergoing chemotherapy.
  • Ribavirin therapy is effective for viral clearance when immunosuppressive therapy is reduced.
  • Extra-hepatic manifestations of HEV are increasingly recognized, indicating a wider organ tropism.

Conclusions:

  • HEV infection requires careful monitoring in immunocompromised individuals due to the risk of severe liver disease.
  • Antiviral therapy, such as ribavirin, is crucial for managing persistent HEV infections.
  • Further research is needed to understand the full spectrum of HEV tropism and associated clinical conditions.